The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global veterinary vaccines market size reached US$ 11.12 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 19.65 Billion by 2027, exhibiting a growth rate (CAGR) of 9.60% during 2022-2027.
Veterinary vaccines represent bio-prepared immunizations that are administered to domestic animals or wild species through parenteral and oral routes to stimulate protective immune responses without causing the disease itself. They involve inactivated, live attenuated and recombinant vaccines as some common medications. These inoculations aid in reducing animal suffering, enhancing immune efficiency, and preventing the risk of developing and transmitting various contagious zoonotic diseases. Apart from this, veterinary vaccines are cost-effective, reliable, and offer long-term prevention, due to which they are also used to increase the production of livestock across the globe.
The global veterinary vaccines market is majorly driven by the increasing demand for effective immunization products and the rising prevalence of various infectious epizootic disorders. This can be further attributed to the domestication of both companion and livestock animals across the globe and the enhanced focus on pet health. In line with this, extensive investments by governments in the pharmaceutical sector to improve novel veterinary vaccine manufacturing procedures are acting as another growth-inducing factor. Additionally, the introduction of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) vaccines with improved product stability, efficacy, and route administration approach is contributing to the market growth. Besides this, the innovation of intramuscular needle-free vaccine injections and growing awareness amongst consumers regarding their beneficial properties, such as enhanced safety and less pain, is propelling the market growth. Moreover, the fueling need for veterinary vaccines to prevent the transmission of disease-carrying microbes from livestock-based products, including milk, meat, leather, eggs, and wool, is positively stimulating the market growth. Other factors, such as significant improvements in the healthcare infrastructure, ongoing research and development (R&D) activities, and strategic collaborations amongst key players to enhance the efficiency of veterinary vaccines, are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global veterinary vaccines market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on vaccine type, technology, route of administration and distribution channel.
Breakup by Vaccine Type:
Breakup by Technology:
Breakup by Route of Administration:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco Animal Health Incorporated, Hester Biosciences Limited, HIPRA, Indian Immunologicals Limited, Merck & Co. Inc., Neogen Corporation, Phibro Animal Health Corporation, Virbac SA and Zoetis Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Vaccine Type, Technology, Route of Administration, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Boehringer Ingelheim International GmbH, Ceva Santé Animale, Elanco Animal Health Incorporated, Hester Biosciences Limited, HIPRA, Indian Immunologicals Limited, Merck & Co. Inc., Neogen Corporation, Phibro Animal Health Corporation, Virbac SA and Zoetis Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at